Spots Global Cancer Trial Database for hormone receptor positive breast carcinoma

Every month we try and update this database with for hormone receptor positive breast carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy	NCT04379570	Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... HER2 Negative B... Hormone Recepto... Invasive Breast... Prognostic Stag... Prognostic Stag... Prognostic Stag...	Educational Int... Text Message-ba... Motivational In... Best Practice Questionnaire A... Quality-of-Life...	18 Years -	Alliance for Clinical Trials in Oncology
Elacestrant in Preoperative Setting, a Window of Opportunity Study	NCT04797728	Breast Cancer Hormone Recepto...	Elacestrant	18 Years -	SOLTI Breast Cancer Research Group
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.	NCT04305834	Anatomic Stage ... Hormone Recepto... Metastatic Brea... Prognostic Stag...	Abemaciclib Questionnaire A...	70 Years -	City of Hope Medical Center
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors	NCT06120283	Advanced Solid ... Advanced Breast... Metastatic Brea... Hormone-recepto... Hormone Recepto... Hormone Recepto... HER2-negative B... Hormone Recepto... Non-small Cell ...	BGB-43395 Fulvestrant Letrozole	18 Years -	BeiGene
Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer	NCT04720664	Breast Cancer Metastatic Brea... Hormone Recepto...	SM-88	18 Years -	Georgetown University
Intermittent Fasting for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery	NCT05327608	Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Breast Ductal C... HER2 Negative B... Hormone Recepto... Invasive Breast...	Short-Term Fast...	18 Years -	Thomas Jefferson University
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer	NCT03251378	Advanced Solid ... Metastatic Colo... Metastatic Brea... Triple Negative... HER2-negative B... Hormone Recepto... Rectal Cancer	Fruquintinib (H...	18 Years -	Hutchmed
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy	NCT04379570	Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... HER2 Negative B... Hormone Recepto... Invasive Breast... Prognostic Stag... Prognostic Stag... Prognostic Stag...	Educational Int... Text Message-ba... Motivational In... Best Practice Questionnaire A... Quality-of-Life...	18 Years -	Alliance for Clinical Trials in Oncology
Intermittent Fasting for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery	NCT05327608	Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Breast Ductal C... HER2 Negative B... Hormone Recepto... Invasive Breast...	Short-Term Fast...	18 Years -	Thomas Jefferson University
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer	NCT04553770	Early-stage Bre... Hormone Recepto... Invasive Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas...	Anastrozole Therapeutic Con... Trastuzumab Der...	18 Years -	Jonsson Comprehensive Cancer Center
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer	NCT04505826	Hormone Recepto... HER2-negative B...	OP-1250	18 Years -	Olema Pharmaceuticals, Inc.
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer	NCT06224673	HER2 Low Breast... Triple Negative... Hormone-recepto... Hormone Recepto...	ARX788 Computed Tomogr... Biospecimen Col...	18 Years -	University of California, San Francisco
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer	NCT04762979	Hormone Recepto... HER2-negative B... PIK3CA Mutant M...	Alpelisib Fulvestrant Aromatase inhib...	18 Years -	Big Ten Cancer Research Consortium
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas	NCT05565417	Non Small Cell ... Head and Neck S... Triple Negative... Cutaneous Squam... Hormone Recepto... Small Bowel Can... Esophageal Canc... Colorectal Canc... Diffuse Large B... Hodgkin Lymphom... Burkitt Lymphom... Follicular Lymp...	IMT-009 Fruquintinib	18 Years -	Immunitas Therapeutics
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)	NCT04726332	Neoplasm Malign... Epithelial Ovar... Triple Negative... Hormone Recepto... Metastatic Cast...	XL102 Fulvestrant Abiraterone Prednisone	18 Years -	Exelixis
Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer	NCT04305236	Breast Neoplasm Hormone Recepto...	Abemaciclib Fulvestrant	18 Years -	University of California, Irvine
Elacestrant in Preoperative Setting, a Window of Opportunity Study	NCT04797728	Breast Cancer Hormone Recepto...	Elacestrant	18 Years -	SOLTI Breast Cancer Research Group
Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer	NCT04720664	Breast Cancer Metastatic Brea... Hormone Recepto...	SM-88	18 Years -	Georgetown University
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer	NCT04553770	Early-stage Bre... Hormone Recepto... Invasive Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas...	Anastrozole Therapeutic Con... Trastuzumab Der...	18 Years -	Jonsson Comprehensive Cancer Center
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors	NCT03845166	Neoplasm Malign... Renal Cell Carc... Hormone Recepto... Metastatic Cast... Colorectal Canc...	XL092 Atezolizumab Avelumab	18 Years -	Exelixis
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer	NCT04553770	Early-stage Bre... Hormone Recepto... Invasive Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas...	Anastrozole Therapeutic Con... Trastuzumab Der...	18 Years -	Jonsson Comprehensive Cancer Center
CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer	NCT05870813	Breast Cancer HER2-negative B... Hormone Recepto...		18 Years - 60 Years	Institut fuer Frauengesundheit
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer	NCT04498520	Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Hormone Recepto... Locally Advance... Metastatic Brea... Metastatic Endo... Metastatic Fall... Metastatic HER2... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Refractory Brea... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Abexinostat Tos... Fulvestrant Palbociclib	18 Years -	University of California, San Francisco
Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer	NCT04305236	Breast Neoplasm Hormone Recepto...	Abemaciclib Fulvestrant	18 Years -	University of California, Irvine
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors	NCT06120283	Advanced Solid ... Advanced Breast... Metastatic Brea... Hormone-recepto... Hormone Recepto... Hormone Recepto... HER2-negative B... Hormone Recepto... Non-small Cell ...	BGB-43395 Fulvestrant Letrozole	18 Years -	BeiGene
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study	NCT04316117	Anatomic Stage ... Hormone Recepto... Metastatic Brea... Prognostic Stag...	Computed Tomogr... Fludeoxyglucose... Positron Emissi...	18 Years -	Eastern Cooperative Oncology Group
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer	NCT06224673	HER2 Low Breast... Triple Negative... Hormone-recepto... Hormone Recepto...	ARX788 Computed Tomogr... Biospecimen Col...	18 Years -	University of California, San Francisco
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer	NCT04498520	Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Hormone Recepto... Locally Advance... Metastatic Brea... Metastatic Endo... Metastatic Fall... Metastatic HER2... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Refractory Brea... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Abexinostat Tos... Fulvestrant Palbociclib	18 Years -	University of California, San Francisco

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: